INGELHEIM, Germany - Wednesday, 03. August 2022
Growing late-stage research pipeline, addressing areas of high unmet medical need
Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease
Net sales rise currency-adjusted by 9.5 percent to 11.2 billion EUR
(BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far thi
Read more »